Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

目录号: HY-78131 纯度: 99.97%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Ibuprofen ((±)-Ibuprofen) 是一种口服有效的 COX-1 选择性抑制剂，IC₅₀ 值为 13 μM。Ibuprofen 抑制细胞增殖、血管生成，并诱导细胞凋亡 (apoptosis)。Ibuprofen 是一种非甾体抗炎试剂和一氧化氮 (NO) 供体。Ibuprofen可用于疼痛、肿胀、炎症、感染、免疫学、癌症的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ibuprofen Chemical Structure

CAS No. : 15687-27-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥1050	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Ibuprofen:

MCE 顾客使用本产品发表的 15 篇科研文献

Ibuprofen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看所有亚型

COX COX-1 COX-2 COX-3

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
纯度 & 产品资料
参考文献

生物活性

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers^[1]^[2]^[5]^[8].

IC₅₀ & Target^[1]

COX-1

13 μM (IC₅₀)

COX-2

370 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
Bel-7402	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
Caco-2	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
COS-7	IC₅₀	> 1000 μM Compound: Ibuprofen	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HCT-116	IC₅₀	448 μM Compound: IB	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20171760]
HCT-15	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	552 μM Compound: IB	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 20171760]
Huh-7	IC₅₀	37.2 μM Compound: Ibu	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
K562	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	> 100 μM Compound: Ibuprofen	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
MCF7	IC₅₀	> 50 μM Compound: 6	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	92.14 μM Compound: Ibuprofen	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
Neutrophil	IC₅₀	12.1 μM Compound: Ibuprofen	Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay	[PMID: 18950230]
Neutrophil	IC₅₀	27.53 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins	[PMID: 20839880]
Neutrophil	IC₅₀	32.55 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry	[PMID: 17822293]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PC-3	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
PC-3	IC₅₀	> 50 μM Compound: Ibuprofen	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
RAW264.7	IC₅₀	0.39 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	0.86 μM Compound: Ibuprofen	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	14.4 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	IC₅₀	1483.87 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	2.1 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	IC₅₀	3309.84 μM Compound: Ibuprofen	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 28408221]
RAW264.7	IC₅₀	54.5 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
SK-LU-1	IC₅₀	90.61 μM Compound: Ibuprofen	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
TERT-RPE1	IC₅₀	> 40 μM Compound: 6	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
U-251	IC₅₀	> 1000 μM Compound: Ibuprofen	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	> 50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]

体外研究
(In Vitro)

Ibuprofen（24 小时）抑制 COX-1 和 COX-2 活性，IC₅₀ 值分别为 13 μM 和 370 μM^[1]。
Ibuprofen (500 μM, 48 小时) 抑制细胞增殖和血管生成，并诱导 AGS 细胞 (腺癌胃细胞系) 凋亡^[2]。
Ibuprofen (500 μM, 48 小时) 下调 AGS 细胞中 Akt、VEGF-A、PCNA、Bcl2、OCT3/4 和 CD44 基因的转录，但上调野生型 P53 和 Bax 基因的 RNA 水平^[2]。
Ibuprofen (500 μM, 24 小时) 可恢复微管重组、微管依赖性细胞内胆固醇转运，并诱导囊性纤维化 (CF) 细胞模型和原代 CF 鼻上皮细胞中微管延伸至细胞周围^[3]。
Ibuprofen（500 μM，24 小时）通过光敏化过程增强 MCF-7 细胞和 MDA-MB-231 细胞中紫外线诱导的细胞死亡^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	AGS cells
Concentration:	100-1000 μM
Incubation Time:	24 h, 48 h
Result:	Inhibited AGS cell viability with IC₅₀ values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).

体内研究
(In Vivo)

Ibuprofen（300 mg/kg；口服；每日一次，连续 14 天）在产后乳腺癌模型中减缓了整体肿瘤生长，增强了抗肿瘤免疫特性，且没有不良的自身免疫反应^[5]。
Ibuprofen（60 mg/kg；ih；每隔一天一次，持续 15 天）可降低奥沙利铂诱发的慢性周围神经病变大鼠模型中发生神经病变的风险^[6]。
Ibuprofen（20 mg/kg；口服；每 12 小时一次，共 5 次）会减少肌肉生长（平均肌纤维横截面积），但不影响冈上肌腱对运动的适应性调节^[7]。
Ibuprofen（35 mg/kg；口服；每日两次）可减轻大鼠慢性肺部感染模型对铜绿假单胞菌的炎症反应^[8]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)^[5]
Dosage:	300 mg/kg, daily for 14 days
Administration:	Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)
Result:	Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells. Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.

Animal Model:	Oxaliplatin‑induced peripheral neuropathy^[6]
Dosage:	60 mg/kg, every second day for 15 days
Administration:	Subcutaneous injection
Result:	Lowered sensory nerve conduction velocity (SNCV).

Clinical Trial

分子量

206.28

Formula

C₁₃H₁₈O₂

CAS 号

15687-27-1

性状

固体

颜色

White to off-white

中文名称

布洛芬；异丁苯丙酸；异丁洛芬

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (484.78 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.8478 mL	24.2389 mL	48.4778 mL
5 mM	0.9696 mL	4.8478 mL	9.6956 mL
10 mM	0.4848 mL	2.4239 mL	4.8478 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用，-20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.97%

选择批次：

Data Sheet (662 KB) SDS (393 KB)

COA (284 KB) LCMS (89 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7. [Content Brief]

[2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015 May;36(5):3237-43. [Content Brief]

[3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L317-27. [Content Brief]

[4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. Sci Rep. 2017 Aug 21;7(1):8885. [Content Brief]

[5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018 Oct 1;6(1):98. [Content Brief]

[6]. Thomas Krøigård, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. Exp Brain Res. 2019 Oct;237(10):2645-2651. [Content Brief]

[7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. Am J Sports Med. 2016 Sep;44(9):2237-45. [Content Brief]

[8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186-92. [Content Brief]

Ibuprofen 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.8478 mL	24.2389 mL	48.4778 mL	121.1945 mL
	5 mM	0.9696 mL	4.8478 mL	9.6956 mL	24.2389 mL
	10 mM	0.4848 mL	2.4239 mL	4.8478 mL	12.1194 mL
	15 mM	0.3232 mL	1.6159 mL	3.2319 mL	8.0796 mL
	20 mM	0.2424 mL	1.2119 mL	2.4239 mL	6.0597 mL
	25 mM	0.1939 mL	0.9696 mL	1.9391 mL	4.8478 mL
	30 mM	0.1616 mL	0.8080 mL	1.6159 mL	4.0398 mL
	40 mM	0.1212 mL	0.6060 mL	1.2119 mL	3.0299 mL
	50 mM	0.0970 mL	0.4848 mL	0.9696 mL	2.4239 mL
	60 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0199 mL
	80 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5149 mL
	100 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2119 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

Customer Review

Other Forms of Ibuprofen:

MCE 顾客使用本产品发表的 15 篇科研文献

Ibuprofen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Ibuprofen 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Ibuprofen (Synonyms: 布洛芬; (±)-Ibuprofen)

Customer Review

Other Forms of Ibuprofen:

Ibuprofen 相关抗体

MCE 顾客使用本产品发表的 15 篇科研文献

Ibuprofen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Ibuprofen 相关抗体:

摩尔计算器

稀释计算器

Ibuprofen 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z